The Use of “Acellbia”—A Biosimilar of Rituximab in Systemic Sclerosis

The possibilities of modern therapy for systemic sclerosis (SSc) remains limited, since most of the used drugs do not have a disease-modifying effect. This encourages the study of new approaches that potentially affect the fundamental pathological processes underlying the disease. One example is ant...

Full description

Saved in:
Bibliographic Details
Published inDoklady. Biochemistry and biophysics Vol. 517; no. 1; pp. 140 - 147
Main Authors Ananyeva, L. P., Garzanova, L. A., Desinova, O. V., Shayakhmetova, R. U., Starovoitova, M. N., Koneva, O. A., Ovsyannikova, O. B., Glukhova, S. I., Nasonov, E. L.
Format Journal Article
LanguageEnglish
Published Moscow Pleiades Publishing 01.08.2024
Springer Nature B.V
Subjects
Antineutrophil cytoplasmic antibodies
Biochemistry
Biological and Medical Physics
Biological products
Biomedical and Life Sciences
Biophysics
Biosimilar Pharmaceuticals - pharmacology
Biosimilar Pharmaceuticals - therapeutic use
Cell therapy
Genetic engineering
Humans
Life Sciences
Lymphocytes B
Molecular Biology
Rheumatoid arthritis
Rituximab
Rituximab - pharmacology
Rituximab - therapeutic use
Scleroderma
Scleroderma, Systemic - drug therapy
Systemic sclerosis
Vasculitis
Russia
rituximab
systemic sclerosis
acellbia
Online AccessGet full text

Cover

More Information
Summary:The possibilities of modern therapy for systemic sclerosis (SSc) remains limited, since most of the used drugs do not have a disease-modifying effect. This encourages the study of new approaches that potentially affect the fundamental pathological processes underlying the disease. One example is anti-B-cell therapy, in particular rituximab (RTX). Until now RTX does not have a registration for the treatment of SSc, but there is a large positive experience of its use, which is reflected in recent meta-analyses and clinical recommendations. Complicated and expensive methods for obtaining genetically engineered biological drugs (biologics) have contributed to the emergence of more accessible biosimilars, one of which is the RTX biosimilar, Acellbia (Biocad, Russian Federation). The ‘‘biosimilar’’ versions of RTX might reduce the cost of therapy and increase patients accessibility to this treatment option. The RTX biosimilar Acellbia (ACB) has received approval in Russian Federation in 2014 for all indications held by reference RTX (including rheumatoid arthritis and ANCA-associated vasculitis).
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
ISSN:1607-6729
1608-3091
1608-3091
DOI:10.1134/S1607672924700844